ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "innate immunity"

  • Abstract Number: 2330 • 2017 ACR/ARHP Annual Meeting

    Evidence for Alternatively Activated (M2) Macrophage Activation in Patients with Enthesitis Related Arthritis Category of Juvenile Idiopathic Arthritis

    Amita Aggarwal1, Priyanka Gaur2 and Akhilesh Yadav3, 1Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, 2Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, 3Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

    Background/Purpose: Among juvenile idiopathic arthritis (JIA), enthesitis related arthritis (ERA) category includes most children with juvenile onset spondyloarthropathy (SpA). Synovial fluid from patients with SpA…
  • Abstract Number: 2577 • 2017 ACR/ARHP Annual Meeting

    Segmented Filamentous Bacteria Colonization Exacerbate Lupus Nephritis in NZM2410 Mice and Causes an Expansion of Intestinal Group 3 Innate Lymphoid Cells

    Giancarlo R. Valiente1, Jeffrey Hampton2, Takuma Wada3, Perry Blough3, William Willis4, Nicholas A. Young4, Lai-Chu Wu5 and Wael Jarjour6, 1Rheumatology & Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, 2Immunology and Rheumatoloty, The Ohio State University Wexner Medical Center, Columbus, OH, 3The Ohio State University, Columbus, OH, 4Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, 5Biological Chemistry and Pharmacology, The Ohio State University Wexner Medical Center, Columbus, OH, 6Department of Rheumatology/Medicine, Ohio State University, Columbus, OH

    Title: Segmented Filamentous Bacteria Colonization Exacerbate Lupus Nephritis in NZM2410 Mice and Causes an Expansion of Intestinal Group 3 Innate Lymphoid Cells Background/Purpose: Innate Lymphoid…
  • Abstract Number: 2643 • 2017 ACR/ARHP Annual Meeting

    HO-1 Expression in Monocytes Might Regulate Kidney Damage in Lupus Nephritis Patients

    Loreto Cuitino1,2, Javiera Obreque1,2, Patricia Gajardo-Meneses1,2, Gonzalo P. Méndez2,3, Alexis M. Kalergis2,4 and Carolina Llanos1,2, 1Departamento de Inmunología Clínica y Reumatología, Santiago, Chile, 2Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile, 3Departamento de Anatomía Patológica, Santiago, Chile, 4Millennium Institute on Immunology and Immunotherapy and Departamento de Endocrinología, Santiago, Chile

    Background/Purpose: It is well established that up to 70% of systemic lupus erythematosus (SLE) patients will develop Lupus Nephritis (LN). Recent studies have revealed that…
  • Abstract Number: 2901 • 2017 ACR/ARHP Annual Meeting

    Anti-Inflammatory Mechanism of Lubricin/Proteoglycan 4 (PRG4) in Monosodium Urate (MSU)-Crystal Induced Arthritis in THP-1 Macrophages Is Mediated By NALP3 Inflammasome.

    Anthony M. Reginato1, Changqi Sun2, Tannin Schmidt3, Elsaid Khalid4 and Gregory Jay5, 1Division of Rheumatology, The Warren Alpert School Of Medicine of Brown University, Providence, RI, 2Division of Rheumatology, Rhode Island Hosital/The Warren Alpert School of Medicine of Brown University, Providence, RI, 3Kinesiology and Schulich School of Engineering, University of Calgary, Calgary, AB, Canada, 4Department of Biomedical and Phramaceutical Science, Chapman University School of Pharmacy, Irvine, CA, 5Emergency Medicine and Engineering, The Warren Alpert Medical School Brown University, Providence, RI

    Background/Purpose: Lubricin/proteoglycan-4 (PRG4) is a mucinous glycoprotein secreted by synovial fibroblast and superficial zone chondrocytes. PRG4 has a multifaceted homeostatic role in the joint including…
  • Abstract Number: 403 • 2017 ACR/ARHP Annual Meeting

    Cardiac Immune Cells in SKG Mice with Inflammatory Arthritis before and after Myocardial Infarction

    Christine Hsieh1, Isabella Imhof2, Luyi Li3, Erene Niemi1, Matthew Bell1, Joel Karliner4 and Mary Nakamura5, 1Medicine, SFVA/UCSF, San Francisco, CA, 2Medicine, SFVA/NCIRE, San Francisco, CA, 3SFVA/UCSF, San Francisco, CA, 4Medicine, SFVA/UCSF, San, CA, 5Department of Medicine, Division of Rheumatology, UCSF/SFVA, San Francisco, CA

    Background/Purpose: Cardiovascular disease is a major cause of morbidity and mortality in patients with rheumatoid arthritis (RA). RA patients have an increased incidence of both…
  • Abstract Number: 544 • 2017 ACR/ARHP Annual Meeting

    Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF-06650833, a Novel, Potentially First-in-Class Inhibitor of Interleukin-1 Receptor Associated Kinase-4 (IRAK-4) in Healthy Subjects

    Spencer Danto1, Negin Shojaee1, Cheryl Li1, Steven A. Gilbert2, Ravi Shankar Singh1, Zorayr Manukyan1 and Iain Kilty1, 1Worldwide Research and Development, Pfizer, Inc., Cambridge, MA, 2Pfizer, Inc., Cambridge, MA

    Background/Purpose: IRAK‑4 is a key node in innate immune signaling and is activated by the interleukin (IL)‑1 family receptors (IL‑1R, IL‑18R, and IL‑33R), in addition…
  • Abstract Number: 1062 • 2017 ACR/ARHP Annual Meeting

    Ptpn22 Regulates Synovial Slam Family Receptor Expression during Toll-like Receptor-Driven Suppression of Inflammatory Arthritis

    David Ewart1, Juan Abrahante Lloréns2 and Erik J. Peterson3, 1Rheumatology, University of Minnesota, Minneapolis, MN, 2Informatics Institute (UMII), University of Minnesota, Minneapolis, MN, 3Center for Immunology/Department of Medicine, University of Minnesota, Minneapolis, MN

    Background/Purpose: Genetic factors contribute strongly to Rheumatoid arthritis (RA) risk. Protein tyrosine phosphatase non-receptor 22 [PTPN22] encodes the hematopoietic-specific Lymphoid Phosphatase [“Lyp”].  A PTPN22 coding…
  • Abstract Number: 1065 • 2017 ACR/ARHP Annual Meeting

    Mucosal-Associated Invariant T Cell Deficiency in Systemic Lupus Erythematosus Is Realted to an Intrinsic Defect in the Ca2+/Calcineurin/NFAT1 Signaling Pathway

    Yong-Wook Park1, Young-Nan Cho2, Hye-Mi Jin1, Tae-Jong Kim3 and Seung-Jung Kee4, 1Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, Korea, Republic of (South), 2Rheumatology, Chonnam National University Hospital and Medical School, Gwangju, MN, Korea, Republic of (South), 3Chonnam Nat`l University Medical School&Hospital, Chonnam, Korea, Republic of (South), 4Laboratory Medicine, Chonnam National University Medical School and Hospital, Gwangju, Korea, Republic of (South)

    Background/Purpose: Mucosal-associated invariant T (MAIT) cells contribute to protection against certain microorganism infections and play an important role in mucosal immunity. However, the role of…
  • Abstract Number: 1068 • 2017 ACR/ARHP Annual Meeting

    Impact of TNF Antagonist Treatment on the Gut Microbiome In Vivo

    Odile Gabay1, Jonathan Vicenty2, Grant Wunderlin3, Linda Tiffany2, Wells Wu4, Vahan Simonyan5 and Kathleen A Clouse6, 1Office of Biotechnology Products /Center for Drug Evaluation and Research DBRRI, U.S. Food and Drug Administration, Silver Spring, MD, 2Office of Biotechnology Products, Center for Drug Evaluation and Research, DBRRI, U.S. Food and Drug Administration, Silver Spring, MD, 3Center for Drug Evaluation and Research CDER DBRRI, U.S. Food and Drug Administration, Silver Spring, MD, 4Center for Biologic Evaluation and Research OMPT, U.S. Food and Drug Administration, Silver Spring, MD, 5Center for Biologic Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, 6Office of Biotechnology Products /Center for Drug Evaluation and Research,DBRRI, U.S. Food and Drug Administration, Silver Spring, MD

    Background/Purpose: Auto-immune diseases are in constant progression in the US. Biologic therapeutics have been used successfully to treat these diseases, but have presented some unique…
  • Abstract Number: 1077 • 2017 ACR/ARHP Annual Meeting

    The Lectin Pathway of the Complement System Is Activated in Patients with Systemic Lupus Erythematosus

    Anne Troldborg1,2, Steffen Thiel3, Marten Trendelenburg4, Justa Friebus-Kardash5, Josephine Nehring5, Rudi Steffensen6, Søren Werner Karlskov Hansen7, Magdalena Janina Laska1, Bent Deleuran8, Jens Christian Jensenius1, Anne Voss9 and Kristian Stengaard-Pedersen10, 1Biomedicine, Aarhus University, Aarhus, Denmark, 2clinical medicine, Aarhus University, Aarhus, Denmark, 3Institute of Biomedicine, Aarhus University, Aarhus, DK, Aarhus, Denmark, 4Department of Biomedicine, Division of Internal Medicine, Basel, Switzerland, 5University Hospital Basel, Division of Internal Medicine, Basel, Switzerland, 6Department of Clinical Immunology, Aalborg University Hospital, Aalborg, Denmark, 7Department of Cancer and Inflammation Research, University of Souther Denmark, Odense, Denmark, 8Department of Biomedicine, Aarhus University, Aarhus, Denmark, 9Rheumatology, Odense University Hospital, Odense, Denmark, 10Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark

    Background/Purpose: The pathogenesis of Systemic Lupus Erythematosus (SLE) involves complement activation. It is well established that activation of complement through the classical pathway (CP) and…
  • Abstract Number: 4 • 2017 Pediatric Rheumatology Symposium

    Microbiota-Dependent Signals Regulate Inflammatory Myelopoiesis in a Murine Model of Macrophage Activation Syndrome

    Lehn K. Weaver1, Chhanda Biswas1, Niansheng Chu1 and Edward M. Behrens2, 1Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, 2Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose: Targeting host-microbiota interactions to limit production of pathogenic myeloid cells that fuel chronic inflammatory responses is of therapeutic interest. Recent evidence suggests that this may…
  • Abstract Number: 10 • 2017 Pediatric Rheumatology Symposium

    Severe Juvenile Arthritis Associated with a De Novo Gain-of-Function Germline Mutation in MYD88

    Keith A. Sikora1, Joshua R. Bennett1, Zuoming Deng2, Wanxia Li Tsai3, April D. Brundidge3, Fatemeh Navid3, Gerlinde Layh-Schmitt3, Eric Hanson4, Massimo G. Gadina5, Louis M. Staudt6, Thomas A. Griffin7 and Robert Colbert3, 1Pediatric Translational Research Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 2Biodata Mining & Discovery, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 3National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 4Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 5Translational Immunology, Office of Science and Technology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 6National Cancer Institute, National Institutes of Health, Bethesda, MD, 7Levine Children’s Hospital at Carolinas Medical Center, Charlotte, NC

    Background/Purpose: Myeloid differentiation primary response 88 (MyD88) is a critical adaptor protein that connects Toll-like and IL-1 receptor signaling to activation of NF-κB. Germline loss-of-function…
  • Abstract Number: 2068 • 2016 ACR/ARHP Annual Meeting

    Type 2 Innate Lymphoid Cells – Cellular Source of Profibrotic Mediators Rapidly and Persistently Recruited in Experimental Fibrosis and Systemic Sclerosis

    Stefanie Weber1, Thomas Wohlfahrt1, Simon Rauber1, Markus Luber1, Matthias Englbrecht2, Clara Dees3, Christian Beyer4, Oliver Distler5, Georg Schett3, Joerg HW Distler3 and Andreas Ramming4, 1Department of Internal Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 2Department of Internal Medicine 3, Rheumatology & Clinical Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, 3Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, 4Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 5Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland

    Background/Purpose:  We aimed to profile ILC2s in fibrotic tissues and to evaluate the functional impact of IC2s in the pathogenesis of systemic sclerosis (SSc). Methods:…
  • Abstract Number: 2092 • 2016 ACR/ARHP Annual Meeting

    Plasma Soluble Triggering Receptor Expressed on Myeloid Cells-1 Is Elevated in Patients with Thrombotic Primary Antiphospholipid Syndrome.  

    Yair Molad1,2, Yonatan Edel3,4, Yael Pri-Paz Basson5, Elisheva Pokroy-Shapira6, Shirly Oren5, Ariela Dortort5 and Vitaly Kliminski4,7, 1Rheumatology Unit, Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel, 2Laboratory of Inflammation Research, Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, Petach Tikva, Israel, 3Department of Medicine C, Beilinson Hospital, Rabib Medical Center, Petach Tikva, Israel, 4Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 5Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, Petach Tikva, Israel, 6Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel, 7Laboratory of Inflammation Research, Felsenstein Medical Research Center, Rabin Medical Center, Petach Tikva, Israel

    Background/Purpose : Primary antiphospholipid syndrome (PAPS) is characterized by thrombotic and/or obstetrical morbidity in the presence of persistent antiphospholipid antibodies (APLA) and in the absence…
  • Abstract Number: 2408 • 2016 ACR/ARHP Annual Meeting

    Severe Juvenile Arthritis Associated with a De Novo Gain-of-Function Germline Mutation in MYD88

    Keith A. Sikora1, Joshua R. Bennett1, Zuoming Deng2, Wanxia Li Tsai3, April Brundidge3, Fatemeh Navid3, Gerlinde Layh-Schmitt3, Eric Hanson3, Massimo G. Gadina4, Louis M. Staudt5, Thomas A. Griffin6 and Robert A. Colbert3, 1Pediatric Translational Research Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 2Biodata Mining & Discovery, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 3National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 4Translational Immunology Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 5National Cancer Institute, National Institutes of Health, Bethesda, MD, 6Levine Children’s Hospital at Carolinas Medical Center, Charlotte, NC

    Background/Purpose: Myeloid differentiation primary response 88 (MyD88) is a critical adaptor protein that connects Toll-like and IL-1 receptor signaling to activation of NF-κB. Germline loss-of-function…
  • « Previous Page
  • 1
  • …
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology